The purpose of this study is to learn about: * How PF-07328948 is changed and removed from the body after taking * Safety of PF-07328948 * The extent to which undesirable effects can be tolerated after taking PF-07328948 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years old and older * Have body mass index from 18.5 to under 28 kilograms/meter square * Have a total body weight over 50 kilograms (110 pounds) * Do not have a history of blood clots blocking an artery or vein All participants in this study will receive oral daily PF-07328948 at the study clinic for 7 consecutive days. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 10 weeks. During this time, participants will have 1 study visit at the study clinical and 1 contact over the phone.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
10
Oral tablet
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1, 7
Area under the plasma concentration (AUC)
Time frame: Day 1, 7
Number of participants with treatment emergent adverse events
Time frame: First dose through study completion, an average of 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.